Journal: Journal of Clinical Imaging Science

Article Title: Does Contrast Dose Based in Lean body Weight Allow Lesser Volumes on High BMI Patients for CT Angiography?

doi: 10.25259/JCIS_97_2021

Figure Lengend Snippet: (a) MDCT angiogram image with contrast delivery based on lean body weight protocol in patient with BMI of 21.5 shows attenuation of 432 HU and (b) patient with BMI 33 showing CT attenuations 403 HU, respectively. MDCT: Multidimensional computed tomography, BMI: Basal metabolic index, HU: Hounsfield unit.

Article Snippet: The patients were scanned with a 256 slice multidimensional computed tomography (MDCT) (iCT, Philips Health Care).

Techniques: Computed Tomography

Journal: Frontiers in Pharmacology

Article Title: Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies

doi: 10.3389/fphar.2023.1275060

Figure Lengend Snippet: Baseline characteristics of included studies.

Article Snippet: , USA , CCAE/MDCD/MDCR/Optum , SGLT-2i , , 47.9-75.5 , , , 41.0-72.1 , , 131542.

Techniques:

Journal: BMJ Medicine

Article Title: Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM

doi: 10.1136/bmjmed-2023-000651

Figure Lengend Snippet: Description of databases from the Observational Health Data Sciences and Informatics network included in the study.

Article Snippet: The data that support the findings of this study are available to license from IBM (CCAE, MDCD, MDCR), Optum (OCEDM, OEHR), and IQVIA (IMRD).

Techniques:

Journal: BMJ Medicine

Article Title: Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM

doi: 10.1136/bmjmed-2023-000651

Figure Lengend Snippet: Proportional incident use of second line antihyperglycaemic drugs in United States national databases, United States health system. CCAE=IBM MarketScan Commercial Claims and Encounters Data; CUIMC=Columbia University Irving Medical Centre; DPP-4i=dipeptidyl peptidase-4 inhibitors; FLPD=France Longitudinal Patient Database; GDA=Germany Disease Analyser; GLP-1 RA=glucagon-like peptide-1 receptor agonist; HIC=Health Informatics Centre at the University of Dundee; JHM=Johns Hopkins Medicine; MDCR=IBM Health MarketScan Medicare Supplemental and Coordination of Benefits Database; OCEDM=Optum Clinformatics Extended Data Mart-Date of Death; OEHR=Optum de-identified Electronic Health Record Dataset; SGLT2i=sodium-glucose cotransporter 2 inhibitor; SIDIAP=Information System for Research in Primary Care; STARR=Stanford Medicine; SU=sulfonylurea; USOC=United States Open Claims; VA=Department of Veterans Affairs Healthcare System

Article Snippet: The data that support the findings of this study are available to license from IBM (CCAE, MDCD, MDCR), Optum (OCEDM, OEHR), and IQVIA (IMRD).

Techniques:

Journal: BMJ Medicine

Article Title: Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM

doi: 10.1136/bmjmed-2023-000651

Figure Lengend Snippet: Proportional first incident use of glucagon-like peptide-1 receptor agonists as second line therapy after metformin in patients with established cardiovascular disease, and patients without established cardiovascular disease. ALPD=Australia Longitudinal Patient Database Practice Profile; CCAE=IBM MarketScan Commercial Claims and Encounters Data; CUIMC=Columbia University Irving Medical Center; FLPD=France Longitudinal Patient Database; GDA=Germany Disease Analyser; GLP-1 RA=glucagon-like peptide-1 receptor agonist; HIC=Health Informatics Centre at the University of Dundee; HKHA=Hong Kong Hospital Authority; IMRD=UK-IQVIA Medical Research Data; JHM=Johns Hopkins Medicine; MDCD=IBM Health MarketScan Multi-State Medicaid Database; MDCR=IBM Health MarketScan Medicare Supplemental and Coordination of Benefits Database; OCEDM=Optum Clinformatics Extended Data Mart - Date of Death; OEHR=Optum de-identified Electronic Health Record Dataset; SIDIAP=Information System for Research in Primary Care; STARR=Stanford Medicine; USOC=United States Open Claims; VA=Department of Veterans Affairs Healthcare System

Article Snippet: The data that support the findings of this study are available to license from IBM (CCAE, MDCD, MDCR), Optum (OCEDM, OEHR), and IQVIA (IMRD).

Techniques:

Journal: BMJ Medicine

Article Title: Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM

doi: 10.1136/bmjmed-2023-000651

Figure Lengend Snippet: Proportional first incident use of sodium-glucose Cctransporter 2 inhibitors as second line therapy after metformin in (A) patients with established cardiovascular disease, and (B) patients without established cardiovascular disease. ALPD=Australia Longitudinal Patient Database Practice Profile; CCAE=IBM MarketScan Commercial Claims and Encounters Data; CUIMC=Columbia University Irving Medical Centre; FLPD=France Longitudinal Patient Database; GDA=Germany Disease Analyser; HIC=Health Informatics Centre at the University of Dundee; HKHA=Hong Kong Hospital Authority; IMRD=UK-IQVIA Medical Research Data; JHM=Johns Hopkins Medicine; MDCD=IBM Health MarketScan Multi-State Medicaid Database; MDCR=IBM Health MarketScan Medicare Supplemental and Coordination of Benefits Database; OCEDM=Optum Clinformatics Extended Data Mart–Date of Death; OEHR=Optum de-identified Electronic Health Record Dataset; SGLT2i=sodium-glucose cotransporter 2 inhibitor; SIDIAP=Information System for Research in Primary Care; STARR=Stanford Medicine; USOC=United States Open Claims; VA=Department of Veterans Affairs Healthcare System

Article Snippet: The data that support the findings of this study are available to license from IBM (CCAE, MDCD, MDCR), Optum (OCEDM, OEHR), and IQVIA (IMRD).

Techniques:

Journal: Cells

Article Title: The Actin Cytoskeleton Responds to Inflammatory Cues and Alters Macrophage Activation

doi: 10.3390/cells11111806

Figure Lengend Snippet: MHCII surface localization and secretion of the T reg chemokine CCL22 are altered by loss of Arp2/3 complex. ( A ) Left, Representative fluorescence histograms showing MHCII surface levels (APC-A) in WT control vs. WT stimulated (LPS/I), KO control vs. KO stimulated (LPS/I) and WT stimulated versus KO stimulated (LPS/I), obtained by reading 10,000 events via FACS measurement. Plots have been normalized to the mode of the data. Right, Average median intensity of APC-A fluorescence (staining MHCII) from WT and Arpc2-/- macrophages left untreated or stimulated for 24 h with LPS/IFNγ, n= 3 independent experiments. ** p -value = 0.0089. ( B ) Left, representative images of surface MHCII staining from WT and Arpc2-/- macrophages at 24 h LPS/ IFNγ stimulation. Scale bar = 30 µm. Right, average cellular MHCII surface staining. Error bars represent standard error of the mean. N = 3 independent experiments with at least 29 cells analyzed per condition in each experiment. ( C ) Average CCL22 chemokine secretion by WT and Arpc2-/- macrophages at baseline or after 24 h of LPS/IFNγ stimulation, as measured by ELISA. N = 4 independent experiments, with p -values obtained via unpaired t-test. Error bars represent standard error of the mean. * p -value ≤ 0.05. ( D ) Left, Mouse chemokine array blot of WT and Arpc2-/- culture medium after 24 h LPS/IFNγ stimulation. Right, quantification of blot intensity for the 10 chemokines detected in these samples. Numbering on the graph corresponds to numbers on the raw blot data above. Each chemokine is spotted onto the membrane in duplicate. N = 2 independent experiments. Error bars represent standard error of the mean. * p -value ≤ 0.05. ( E ) Average IL6 and TNFα secretion by WT and Arpc2-/- macrophages at baseline or after 24 h of LPS/IFNγ stimulation, as measured by ELISA. Means are color coded by experiment. Error bars represent standard error of the mean. N = 4 independent experiments.

Article Snippet: IL-6, TNFa and CCL22/MDC1 levels were measured using a mouse IL-6 ELISA kit (Millipore; Burlington, MA, USA; #RAB0308), a mouse Tumor necrosis Factor alpha ELISA kit (Millipore, Burlington, MA, USA; #RAB0477), and mouse CCL22/MDC1 Elisa kit (RayBiotech; Peachtree Corners, GA, USA #ELM-MDC-1).

Techniques: Fluorescence, Staining, Enzyme-linked Immunosorbent Assay